Dr. Zeng's research focuses on translational immuno-oncology, particularly the development and optimization of CAR T-cell therapies, including CD70- and CD5-targeted constructs with integrated safety mechanisms, supported by single-cell transcriptomic analysis.
- MD, Tongji Medical College, Huazhong University of Science and Technology, 2018
- MPH, Johns Hopkins Bloomberg School of Public Health
- Internal Medicine Residency, Cleveland Clinic Foundation/Akron General Program, 2024
Education & Training
Cheng J, Ge T, Zhu X, Wang J, Zeng Y, Mu W, Cai H, Dai Z, Jin J, Yang Y, Hu G, Mao X, Zhou J, Shu L., Huang L. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother. 2023: 72(7):2331-2346.
Cheng J, Zhao Y, Hu H, Tang L, Zeng Y, Deng X, Ding S, Guo AY, Li Q, Zhu X. Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics. Cancer Immunol Immunother. 2023; 72(10):3163-3174.
Lin H, Cheng J, Zhu L, Zeng Y, Dai Z, Zhang Y, Zhu X, Mu W. Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control. Blood Cancer J. 2024; 14(1):98.
Cheng J, Hu X, Dai Z, Zeng Y, Jin J, Mu W, Wei Q, Jia X, Liu J, Xie M, Luo Q, Hu G, Wang G, Zhu X, Zhou J, Xiao M, Wang J, Tan T, Huang L. Targeting intracellular LMP2 with costimulatory signal-armed antibody-like TCR T cells. JCI Insight. 2025; 10(10):e178572.
